Scarica l'app Stockscreener
3.06
3.73%
0.11
Dopo l'orario di chiusura:
3.10
0.04
+1.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.95
Aprire:
$2.96
Volume 24 ore:
57,081
Relative Volume:
0.42
Capitalizzazione di mercato:
$98.57M
Reddito:
-
Utile/perdita netta:
$-12.48M
Rapporto P/E:
-7.8462
EPS:
-0.39
Flusso di cassa netto:
$-7.93M
1 W Prestazione:
+3.03%
1M Prestazione:
-8.25%
6M Prestazione:
-0.65%
1 anno Prestazione:
-2.86%
Intervallo 1D:
$2.96
$3.09
Intervallo di 1 settimana:
$2.92
$3.09
Portata 52W:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Nome
Anixa Biosciences Inc
Settore
Industria
Telefono
408-708-9808
Indirizzo
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Confronta ANIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.06 | 95.99M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Maxim Group | Buy |
| 2022-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-12 | Iniziato | H.C. Wainwright | Buy |
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Anixa Biosciences, Inc Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology - MarketScreener
Anixa biosciences secures Chinese patent for breast cancer vaccine - Investing.com
First-Ever Chinese Patent Granted: Anixa's Revolutionary Breast Cancer Vaccine Targets World's Largest Market - Stock Titan
Anixa Biosciences: Buy Rating Reiterated, Price Target Raised to $10 - AInvest
Anixa Biosciences shares rise 1.89% intraday after treating second patient in fourth cohort of ovarian cancer CAR-T clinical trial. - AInvest
Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort - TipRanks
30x Dose Increase Shows No Toxicity: Anixa's Novel Ovarian Cancer CAR-T Therapy Reaches Major Milestone - Stock Titan
Can Anixa Biosciences Inc. continue delivering strong returns2025 Technical Patterns & High Return Trade Opportunity Guides - thegnnews.com
Combining price and volume data for Anixa Biosciences Inc.2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Is this a good reentry point in Anixa Biosciences Inc.2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser
Is Anixa Biosciences Inc. benefiting from interest rate changesJuly 2025 Trade Ideas & Proven Capital Preservation Tips - thegnnews.com
Will Anixa Biosciences Inc. outperform the market in YEAR2025 Market Outlook & Fast Exit Strategy with Risk Control - thegnnews.com
Anixa Biosciences Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Volatility Report & Community Verified Trade Alerts - sundaytimes.kr
Anixa Biosciences Bets On Cancer Vaccines And CAR-T Trials - Finimize
Can Anixa Biosciences Inc. sustain its profitabilityJuly 2025 PostEarnings & Free Community Consensus Stock Picks - thegnnews.com
Anixa Biosciences Inc. Forms Bullish Flag — Upside Ahead2025 Top Gainers & Weekly Breakout Opportunity Watchlist - sundaytimes.kr
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - BioSpace
Anixa Biosciences Receives Patent Extension for CAR-T Technology - AInvest
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
Anixa Biosciences Receives Additional US Patent for CAR-T Technology, Extending Protection to 2045 - AInvest
Anixa Biosciences secures new patent for solid tumor CAR-T technology - Investing.com India
Anixa Biosciences secures new patent for solid tumor CAR-T technology By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Issuance Of Additional U.S. Patent For CAR-T Technology - Barchart.com
Tools to assess Anixa Biosciences Inc.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
Anixa Biosciences shares rise 1.68% after-hours as Dr. Wenham to present at Ovarcoming Cancer Conference. - AInvest
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - The Malaysian Reserve
Breakthrough CAR-T Therapy for Ovarian Cancer: Moffitt's Chair Reveals Latest Trial Progress at Major Conference - Stock Titan
What momentum shifts mean for Anixa Biosciences Inc.Free Daily Volume Spike Trading Signals - Newser
D. Boral Capital Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX) - Defense World
Competitive Positioning of Anixa Biosciences Inc.: Is It Leading or LaggingPortfolio Positioning Strategy With Timing - Newser
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial - BioSpace
Director Makes Bold Move with Major Stock Purchase in Anixa Biosciences - TipRanks
Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating - TipRanks
Anixa plans to begin Phase 2 of breast cancer vaccine trial - TipRanks
Anixa Biosciences director Titterton buys $30k in stock By Investing.com - Investing.com Canada
Anixa Biosciences director Titterton buys $30k in stock - Investing.com India
Breakthrough Breast Cancer Vaccine Achieves 70% Immune Response, FDA Clears Path for Phase 2 Trial - Stock Titan
How does Anixa Biosciences Inc. compare to its industry peersStrong return on assets - Jammu Links News
What is Anixa Biosciences Inc. company’s growth strategyTriple-digit growth rates - Jammu Links News
How many analysts rate Anixa Biosciences Inc. as a “Buy”Turn volatility into profit opportunities - Jammu Links News
Is Anixa Biosciences Inc. stock overvalued or undervaluedTurn volatility into profit opportunities - Jammu Links News
What is the dividend policy of Anixa Biosciences Inc. stockCapitalize on momentum stocks early - Jammu Links News
What are analysts’ price targets for Anixa Biosciences Inc. in the next 12 monthsDiscover high-impact stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Anixa Biosciences Inc.Free Investment Risk Control - Jammu Links News
When is Anixa Biosciences Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Why is Anixa Biosciences Inc. stock attracting strong analyst attentionGet real-time updates on market movers - Jammu Links News
Should I hold or sell Anixa Biosciences Inc. stock in 2025Turn volatility into profit opportunities - Jammu Links News
What catalysts could drive Anixa Biosciences Inc. stock higher in 2025Unlock powerful stock screening tools - Jammu Links News
How does Anixa Biosciences Inc. generate profit in a changing economyAchieve rapid growth with smart investments - Jammu Links News
RSI Crosses Above 30 for Anixa Biosciences Inc. — Reversal in SightWeekly Top Gainers Forecast Watchlist Released - metal.it
Anixa Biosciences Secures Canadian Patent for Breast Cancer Vaccine Technology - AInvest
Anixa Biosciences Inc Azioni (ANIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anixa Biosciences Inc Azioni (ANIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):